Plain-English translation of NCT07028528 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether Levagen+, a supplement containing an ingredient called palmitoylethanolamide (PEA), can help relieve the symptoms of nerve pain caused by diabetes. Researchers want to see if this medication works better than a placebo (a dummy capsule with no active ingredient) in reducing nerve-related symptoms like numbness, tingling, and pain in the hands and feet.
Diabetes can damage nerves over time, causing chronic pain and discomfort that is difficult to treat with existing medications. This trial exists to see whether this medication might offer a new treatment option for people living with this painful complication.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take one capsule of either the active medication or placebo twice daily with food for 12 weeks. You'll have remote (phone or video) check-in visits every 3 weeks, and you'll need to attend a local pathology centre for a blood draw. Throughout the study, you'll be asked not to change your diet or exercise routine and not to participate in other clinical trials. The entire study lasts 12 weeks from start to finish.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
Australia